This website is not owned by Johnson & Johnson (New Zealand) Ltd, and we do not review or control the content of this website. Products discussed on this website may not be approved for use or may be approved for different indications in your country. Before using any medical device, review all relevant Instructions for Use, Package Inserts or Summary of Product Characteristics. We do not endorse the use or promotion of unapproved products or indications. Any demonstrations of approved medical devices should be considered as information only and are not a surgical training guide.
Ethicon provides a comprehensive portfolio of adjunctive haemostats, delivering both clinical efficacy and economic efficiency. Each haemostasis agent is designed to address a range of intraoperative bleeding challenges.1-10
Real-world evidence study shows a comprehensive portfolio with a systematic approach to surgical adjunctive haemostat use delivers economic efficiencies1
Reduce Overall Spend
Partnering with Ethicon to leverage portfolio contract strategies saved ^ $168K1.
^ Calculations done in US dollars
Optimise Product Usage
Spend per haemostat unit trended downward 15% over the year by utilising a more cost-effective solution.1
Deliver Surgeon Satisfaction
When asked about the success of both product conversion and implementation of the HOP program, surgeons and nurses were "Very Satisfied," based on a survey using a five-point Likert scale.1
Why Ethicon Biosurgery?
Broad Adjunctive Haemostat Portfolio
Ethicon has a broad portfolio of adjunctive haemostats, each designed to manage a range of bleeding challenges surgical teams may encounter. The breadth of the portfolio helps enable the right adjunctive haemostat to be used at the right time.1
Ethicon's comprehensive portfolio and systematic approach to bleeding management allow you to manage category growth in 3 ways: supplier standardisation, product utilisation, and product consolidation. Implementation of this approach helps control bleeding situations and delivers cost efficiences.1
All calculations are in USD. The economic analysis was performed according to a US hospital data set on this page.
Legacy of Innovation
Ethicon has been committed to adjunctive haemostats for more than 60 years, beginning with SURGICEL® Original11. We continue to drive innovation in this space to provide surgical teams with relevant and clinically effective products such as SURGICEL® Powder Absorbable Haemostat.
Partners in Education
Ethicon is committed to working with your surgical teams to provide product education, in-service and relevant professional education events to elevate knowledge in this space and drive a standardised approach to bleeding management.
Different Bleeding Situations Require Different Solutions
Surgicel® Family of Absorbable Haemostats
Addresses various forms of continouous oozing bleeding that will not stop with compression or simple packing. This bleeding is more time consuming than it is difficult.1
Surgiflo® with Thrombin
Optimal for bleeding that occurs in tight and irregular spaces and when you cannot see the exact source of the bleed. Also, addresses possible concerns that accessing a tight space will cause more harm1.
*Compared to SURGICEL® Original Absorbable Hemostat.
†Compared to 10 mL FLOSEAL; Hemostatic Matrix.
- Ferko N, Danker W, Gangoli G. A systematic approach to surgical hemostat use supports standardization and cost efficiencies. Healthcare Purchasing News. 2017;41(11):34-35.
- Notarnicola A, Moretti L, Martucci A, et al. Comparative efficacy of different doses of fibrin sealant to reduce bleeding after total knee arthroplasty. Blood Coagul Fibrinolysis. 2012;23(4):278-284.
- Molloy DO, Archbold HA, Ogonda L, McConway J, Wilson RK, Beverland DE. Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial. J Bone Joint Surg Br. 2007;89(3):306-309.
- Sabatini L, Trecci A, Imarisio D, Uslenghi MD, Bianco G, Scagnelli R. Fibrin tissue adhesive reduces postoperative blood loss in total knee arthroplasty. J Orthop Traumatol. 2012;13(3):145-151.
- Wang GJ, Hungerford DS, Savory CG, et al. Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trial. J Bone Joint Surg. 2001. 83(10):1503-1505.
- Randelli F, Banci L, Ragone V, Pavesi M, Randelli G. Effectiveness of fibrin sealant after cementless total hip replacement: a double-blind randomized controlled trial. Int J Immunopathol Pharmacol. 2013;26(1):189-197.
- Joseph T, Adeosun A, Paes T, Bahal V. Randomised controlled trial to evaluate the efficacy of TachoComb H patches in controlling PTFE suture–hole bleeding. Eur J Vasc Endovasc Surg. 2004;27(5):549–552.
- Pan HW, Zhong JX, Jing CX. Comparison of fibrin glue versus suture for conjunctival autografting in pterygium surgery: a meta-analysis. Ophthalmology. 2011;118(6):1049-1054.
- Dancey AL, Cheema M, Thomas SS (2010). A prospective randomized trial of the efficacy of marginal quilting sutures and fibrin sealant in reducing the incidence of seromas in the extended l atissimus dorsi donor site. Plast Reconstr Surg. 2010;125(5):1309-1317.
- Ye X, Rupnow MF, Hammond J, Shah M, Farrelly E. Readmission rates and hospital costs associated with fibrin sealant use among patients undergoing orthopaedic surgery. J Orthopaedics. 2011;9(1):e5.
- SURGICEL® Technical Report. 2018. Ethicon, Inc.
©2022 Johnson & Johnson (New Zealand) Ltd. This site is published by Johnson & Johnson (New Zealand) Ltd which is solely responsible for its contents.
This site is intended for Healthcare Professionals from New Zealand only. Ethicon is a business unit of Johnson & Johnson (New Zealand) Ltd. 507 Mount Wellington Highway, Mount Wellington, Auckland, 1060, New Zealand.